Moderna ’s COVID-19 Vaccine Enters Final Testing Phase, As Researchers Dose the Study’s First Volunteer

Moderna Therapeutics and the National Institute of Allergy and Infectious Diseases (NIAID) announced today that researchers had injected the first volunteer in the first U.S. coronavirus vaccine to reach the final, phase 3 stage of testing. That person received the shot at 6:45 am eastern time in Savannah, Geo., Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) told reporters during a briefing. Because the trial will randomly assign participants to receive either the vaccine or a placebo, and neither the researchers nor the volunteers will know which they received, that person won’t know until the data is unblinded whether he or she was vaccinated against COVID-19. Ultimately, 30,000 healthy people will be immunized either with the vaccine or a control to determine how effective the shot is in preventing COVID-19. “The collaboration between the NIH and Moderna, with much support from Operation Warp Speed has now reached a point where we have a chance to find out in the real world…what the status of the vaccine is in its ability to protect against disease and be safe,” said Dr. Francis Collins, director of NIH. Moderna is one of a handful of companies receiving federal funding through the government’s Operation Warp Speed program to facilitate development of a COVID-19 vaccine. Because this final phase of testing will focus on how well the vaccine works, as opposed...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news

Related Links:

Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Source: Academic Radiology - Category: Radiology Source Type: research
Publication date: 15 February 2021Source: Personality and Individual Differences, Volume 170Author(s): Brian W. Haas, Fumiko Hoeft, Kazufumi Omura
Source: Personality and Individual Differences - Category: Psychiatry & Psychology Source Type: research
Boosting the sensitivity of in vitroβ-lactam allergy diagnostic tests. Chem Commun (Camb). 2020 Oct 14;56(80):11973-11976 Authors: Peña-Mendizabal E, Morais S, Maquieira Á Abstract The synthesis of structurally new haptens and the development of suitable antigens are essential for boosting the sensitivity of drug allergy diagnostic testing. Unprecedented structural antigens for benzylpenicillin and amoxicillin are characterised and evaluated in a cohort of 70 subjects with a turnkey solution based on consumer electronics. PMID: 33033809 [PubMed - in process]
Source: Chemical Communications - Category: Chemistry Authors: Tags: Chem Commun (Camb) Source Type: research
Authors: Hui KK PMID: 33034297 [PubMed - as supplied by publisher]
Source: Hong Kong Medical Journal - Category: General Medicine Tags: Hong Kong Med J Source Type: research
Authors: Lam PT PMID: 33034296 [PubMed - as supplied by publisher]
Source: Hong Kong Medical Journal - Category: General Medicine Tags: Hong Kong Med J Source Type: research
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): G. Alvarez Bravo, L. RamióTorrentà
Source: Neurologia - Category: Neurology Source Type: research
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): N. Morollón, R. Belvís, A. De Dios, N. Pagès, C. González-Oria, G. Latorre, S. Santos-Lasaosa
Source: Neurologia - Category: Neurology Source Type: research
More News: Academies | African Health | Allergy | Allergy & Immunology | Coronavirus | COVID-19 | Funding | Genetics | Government | Health | Health Management | Infectious Diseases | International Medicine & Public Health | Learning | Measles | Measles Vaccine | National Institutes of Health (NIH) | Outbreaks | SARS | Study | Universities & Medical Training | Vaccines | Websites